Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759 is registered in ClinicalTrials.gov with 4D Molecular Therapeutics as lead sponsor.

NCT NCT07064759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07064759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Lead sponsor
4D Molecular Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
July 22, 2025
Completion date
February 28, 2029
Enrollment
480 (estimated)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd)